Compare · ABT vs MANE
ABT vs MANE
Side-by-side comparison of Abbott Laboratories (ABT) and Veradermics Incorporated (MANE): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both ABT and MANE operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
- ABT is the larger of the two at $200.95B, about 47.0x MANE ($4.28B).
- Over the past year, ABT is down 11.8% and MANE is up 171.8% - MANE leads by 183.6 points.
- MANE has been more active in the news (14 items in the past 4 weeks vs 8 for ABT).
- ABT has more recent analyst coverage (25 ratings vs 6 for MANE).
- Company
- Abbott Laboratories
- Veradermics Incorporated
- Price
- $116.11-0.50%
- $102.33+3.98%
- Market cap
- $200.95B
- $4.28B
- 1M return
- +11.04%
- -8.46%
- 1Y return
- -11.76%
- +171.79%
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NYSE
- NYSE
- IPO
- 2026
- News (4w)
- 8
- 14
- Recent ratings
- 25
- 6
Abbott Laboratories
Abbott Laboratories discovers, develops, manufactures, and sells health care products worldwide. It operates in four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The Established Pharmaceutical Products segment provides generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency, irritable bowel syndrome or biliary spasm, intrahepatic cholestasis or depressive symptoms, gynecological disorder, hormone replacement therapy, dyslipidemia, hypertension, hypothyroidism, Ménière's disease and vestibular vertigo, pain, fever, inflammation, and migraine, as well as provides anti-infective clarithromycin, influenza vaccine, and products to regulate physiological rhythm of the colon. The Diagnostic Products segment offers laboratory systems in the areas of immunoassay, clinical chemistry, hematology, and transfusion; molecular diagnostics systems that automate the extraction, purification, and preparation of DNA and RNA from patient samples, as well as detect and measure infectious agents; point of care systems; cartridges for testing blood; rapid diagnostics lateral flow testing products; molecular point-of-care testing for HIV, SARS-CoV-2, influenza A and B, RSV, and strep A; cardiometabolic test systems; drug and alcohol test, and remote patient monitoring and consumer self-test systems; and informatics and automation solutions for use in laboratories. The Nutritional Products segment provides pediatric and adult nutritional products. The Medical Devices segment offers rhythm management, electrophysiology, heart failure, vascular, and structural heart devices for the treatment of cardiovascular diseases; and diabetes care products, as well as neuromodulation devices for the management of chronic pain and movement disorders. The company was founded in 1888 and is based in North Chicago, Illinois.
Latest ABT
- Abbott receives FDA authorization for world's first dual glucose-ketone sensing technology for people with diabetes
- Abbott Laboratories filed SEC Form 8-K: Regulation FD Disclosure, Other Events, Financial Statements and Exhibits
- Abbott reaches agreements to resolve a portion of litigation involving its specialty formulas for preterm infants
- Abbott and NACHC launch nationwide Food for Health initiative to make nutritious food a core part of healthcare
- EXECUTIVE VICE PRESIDENT Morrone Louis H. sold $642,506 worth of Common shares without par value (5,850 units at $109.83), decreasing direct ownership by 8% to 70,724 units (SEC Form 4)
- Abbott Labs upgraded by Wolfe Research with a new price target
- Abbott and Big Ten bring back 'We Give Blood' as U.S. faces blood supply crisis
- Abbott and Google launch first-of-its-kind partnership to transform everyday health through glucose insights and AI
- SEC Form 10-Q filed by Abbott Laboratories
- FDA Approves Freenome’s SimpleScreen™ CRC Blood-Based Screening Test; Abbott to Commercialize in the U.S.
Latest MANE
- Amendment: SEC Form SCHEDULE 13D/A filed by Veradermics Incorporated
- Director Montanova Capital, Llc sold $80,437,500 worth of shares (750,000 units at $107.25) and converted options into 300,000 shares (SEC Form 4)
- SEC Form 3 filed by new insider Hollander David
- Chief Technical Officer Durso Timothy August exercised 3,452 shares at a strike of $12.19 and sold $4,690,005 worth of shares (43,500 units at $107.82), decreasing direct ownership by 34% to 78,142 units (SEC Form 4)
- Chief Executive Officer Waldman Reid Alexander sold $7,280,713 worth of shares (67,500 units at $107.86) and exercised 3,452 shares at a strike of $12.19, decreasing direct ownership by 27% to 170,824 units (SEC Form 4)
- SEC Form EFFECT filed by Veradermics Incorporated
- Amendment: SEC Form 144/A filed by Veradermics Incorporated
- Director Childs John W sold $10,711,700 worth of shares (100,000 units at $107.12) (SEC Form 4)
- SEC Form 424B3 filed by Veradermics Incorporated
- SEC Form 10-Q filed by Veradermics Incorporated